drugset / Trial / NCT00316407
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effectiveness, safety, tolerability and best dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.
Timeline
- Start
- 2005-08
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 unknown | — |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | — |